Skip to main content
Premium Trial:

Request an Annual Quote

Samraat Raha, Brad Walsh, Grant Cameron

Premium

EraGen Biosciences has appointed Samraat Raha Chief Business Officer, the Madison, Wis.-based company said last week. Raha will be responsible for EraGen’s overall business development, sales, and marketing efforts. In his most recent position, Raha served as vice president of discovery services at Incyte Genomics, where he oversaw the company’s genomic service businesses, including microarrays and bioreagents. Raha has a BA in molecular and cell biology from the University of California, Berkeley.

After leaving the Australian Proteomics Analysis Facility earlier this year, Brad Walsh has started his own company, ProteoMeca. Walsh will serve as CEO of the new proteomics discovery company, which is planning to apply proteomics to agriculture and bacterial systems. ProteoMeca is based in Harbord, Australia.

Grant Cameron has joined Cambridge, UK-based NextGen Sciences as European Commercial Director. Cameron previously served as business director for Sense Proteomic.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.